Targeting complement activation in COVID-19

Abstract excerpt

In this issue of Blood, Yu et al have demonstrated that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins activate complement by engaging the alternative pathway (AP) and that blocking this process by inhibiting factor D or C5 could mitigate SARS-CoV-2–induced immunopathology.(1)

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Complement system in diseases
• Share to COVID-19 Clinical Research Studies
• Share to SARS-CoV-2 and COVID-19 Research